Accelerate Diagnostics Inc Verschuldung / Eigenkapital

Was ist das Verschuldung / Eigenkapital von Accelerate Diagnostics Inc?

Verschuldung / Eigenkapital von Accelerate Diagnostics Inc ist -2.58

Was ist die Definition von Verschuldung / Eigenkapital?



Die Verschuldung zu Eigenkapital ist ein Finanzverhältnis, das den relativen Anteil des Eigenkapitals und der Verschuldung angibt, die zur Finanzierung der Vermögenswerte eines Unternehmens verwendet werden.

The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.

Verschuldung / Eigenkapital von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Accelerate Diagnostics Inc

Was macht Accelerate Diagnostics Inc?

accelerate diagnostics, inc. (nasdaq:axdx), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. the company's revolutionary id/ast platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. in addition to the id/ast development pipeline, the company also owns and licenses its proprietary optichem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.

Unternehmen mit verschuldung / eigenkapital ähnlich Accelerate Diagnostics Inc